HDAC inhibitors restore BRAF inhibitor sensitivity by altering PI3K and survival signaling in melanoma

被引：0
|
作者：
Hersey, Peter [1 ]
Gallagher, Stuart J. [1 ]
机构：
[1] Univ Sydney, Sydney, NSW, Australia
来源：
CANCER RESEARCH | 2018年 / 78卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2018-3684
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3684
引用
收藏
页数：1
相关论文
共 50 条
  • [1] HDAC inhibitors restore BRAF-inhibitor sensitivity by altering PI3K and survival signalling in a subset of melanoma
    Gallagher, Stuart J.
    Gunatilake, Dilini
    Beaumont, Kimberley A.
    Sharp, Danae M.
    Tiffen, Jessamy C.
    Heinemann, Anja
    Weninger, Wolfgang
    Haass, Nikolas K.
    Wilmott, James S.
    Madore, Jason
    Ferguson, Peter M.
    Rizos, Helen
    Hersey, Peter
    INTERNATIONAL JOURNAL OF CANCER, 2018, 142 (09) : 1926 - 1937
  • [2] Development of an HDAC/PI3K dual inhibitor in academia
    Saijo, Ken
    Ishioka, Chikashi
    ANNALS OF ONCOLOGY, 2017, 28 : 49 - 49
  • [3] Inhibitors of pan-PI3K signaling synergize with BRAF or MEK inhibitors to prevent BRAF-mutant melanoma cell growth
    Sweetlove, Melanie
    Wrightson, Emma
    Kolekar, Sharada
    Rewcastle, Gordon W.
    Baguley, Bruce C.
    Shepherd, Peter R.
    Jamieson, Stephen M. F.
    FRONTIERS IN ONCOLOGY, 2015, 5
  • [4] Effective Treatment of Metastatic Melanoma by Combining MAPK and PI3K Signaling Pathway Inhibitors
    Aasen, Synnove Nymark
    Parajuli, Himalaya
    Tuyen Hoang
    Feng, Zichao
    Stokke, Krister
    Wang, Jiwei
    Roy, Kislay
    Bjerkvig, Rolf
    Knappskog, Stian
    Thorsen, Frits
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (17)
  • [5] The RTK/RAS/BRAF/PI3K pathways in melanoma: Biology, small molecule inhibitors, and potential applications
    Haluska, Frank
    Pemberton, Trevor
    Ibrahim, Nageatte
    Kalinsky, Kevin
    SEMINARS IN ONCOLOGY, 2007, 34 (06) : 546 - 554
  • [6] Analysis of BRAF, NRAS and PI3K mutation in primary and metastatic melanoma
    Libra, Massimo
    Malaponte, Grazia
    Callari, Daniela
    D'Assoro, Antonio
    Travali, Salvatore
    Mazzarino, Maria C.
    McCubrey, James A.
    Stivala, Franca
    CANCER RESEARCH, 2006, 66 (08)
  • [7] Detection of BRAF and PI3K mutations in cutaneous melanoma of outdoor workers
    Marconi, Andrea
    Rapisarda, Venerando
    Libra, Massimo
    Proietti, Lidia
    Malaponte, Grazia
    McCubrey, James A.
    Fenga, Concettina
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2012, 30 : S55 - S55
  • [8] RIDR-PI-103, ROS-activated PI3K inhibitor prodrug inhibits cell growth and impairs the PI3K/Akt pathway in BRAF and MEK inhibitor resistant BRAF-mutant melanoma cells.
    Patel, Hima
    Mishra, Rosalin
    Wier, Adam
    Mokhtarpour, Nazanin
    Merino, Edward J.
    Garrett, Joan T.
    CANCER RESEARCH, 2022, 82 (12)
  • [9] Elucidating the role of PI3K lipid effectors in BRAF mutant melanoma
    Parkman, Gennie
    Cho, Joseph
    Holmen, Sheri
    McMahon, Martin
    CANCER RESEARCH, 2020, 80 (16)
  • [10] The small GTPase ARF6 augments BRAF and PI3K expression to promote melanoma survival
    Wang, Junhua
    Rich, Coulson
    Rogers, Aaron
    Holmen, Sheri
    Wolff, Roger
    Grossmann, Allie
    CANCER RESEARCH, 2024, 84 (06)
12345